The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE.
- Author:
Jung Hee KIM
1
;
Dong Hyun SINN
;
Sung Wook SHIN
;
Sung Ki CHO
;
Wonseok KANG
;
Geum Youn GWAK
;
Yong Han PAIK
;
Joon Hyeok LEE
;
Kwang Cheol KOH
;
Seung Woon PAIK
;
Moon Seok CHOI
Author Information
- Publication Type:Original Article
- Keywords: Carcinoma, Hepatocellular; Transarterial chemoembolization; Survival
- MeSH: Carcinoma, Hepatocellular*; Follow-Up Studies; Humans; Liver Neoplasms; Mortality; Response Evaluation Criteria in Solid Tumors; Survival Rate
- From:Clinical and Molecular Hepatology 2017;23(1):42-50
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: We investigated the outcomes of early-stage hepatocellular carcinoma (HCC) patients who showed a complete response (CR) to initial transarterial chemoembolization (TACE), with a focus on the role of scheduled TACE repetition. METHODS: A total of 178 patients with early-stage HCC who were initially treated with TACE and showed a CR based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria on one month follow-up computed tomography (CT) were analyzed. Among them, 90 patients underwent scheduled repetition of TACE in the absence of viable tumor on CT. RESULTS: During a median follow-up period of 4.6 years (range: 0.4-8.8 years), mortality was observed in 71 patients (39.9%). The overall recurrence-free and local recurrence-free survival rates at 1 year were 44.4% and 56.2%. In the multivariable model, scheduled repetition of TACE was an independent factor associated with survival (hazard ratio [95% confidence interval]: 0.56 [0.34-0.93], P=0.025). When stratified using Barcelona clinic liver cancer (BCLC) stage, scheduled repetition of TACE was associated with a favorable survival rate in BCLC stage A patients, but not in BCLC 0 patients. CONCLUSIONS: Scheduled repetition of TACE was associated with better survival for early-stage HCC patients showing a CR after initial TACE, especially in BCLC stage A patients.
